GlassScriptPhysician profile
Marjan Karegar
NPI 1669621884
$14,159.37
in general payments reported to CMS, 2019-2025
59 companies · $2,795 in 2025
The $2,795 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,613 · 2020: $697 · 2021: $417 · 2022: $2,019 · 2023: $2,879 · 2024: $2,740 · 2025: $2,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,335 · Gift: $59.40 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,334.63 |
| Gift | $59.40 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,945.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $942.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $941.96 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $850.85 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $832.81 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $742.94 | 2019-2025 | |
| Abbott Laboratories | $675.66 | 2019-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $582.71 | 2019-2025 | Tirosint, Tirosint, Licart |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.48 | 2019-2025 | Jardiance |
| Amgen INC. | $520.02 | 2019-2025 | Tepezza, Evenity, Repatha |
| Medtronic, INC. | $438.16 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Abbvie INC. | $422.11 | 2019-2024 | |
| Mannkind Corporation | $380.15 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $373.72 | 2019-2025 | Farxiga |
| Amneal Pharmaceuticals LLC | $363.19 | 2019-2024 | Unithroid |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjan Karegar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.